Skip to content

Study · Not a test of the peptide alone · 2026

9 results

Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis.

Chen Q, Chen T, Lin W, Chen X

PloS one10 Jun 2026

PMID42268869 (opens in a new tab)PMCIDPMC13252742 (opens in a new tab)DOI10.1371/journal.pone.0351059 (opens in a new tab)PepBankPUB-42268869
Download PDFPubMedAsk about this study
Jump to 9 results

Summary

ObjectiveFrom the perspective of China's basic medical insurance, to evaluate the cost-effectiveness of semaglutide versus dulaglutide for type 2 diabetes mellitus (T2DM) in China, informing clinical and health policy decisions.MethodsThis study employed a Markov model to simulate the disease progression of T2DM over a 25-year time horizon. Transition probabilities between health states were sourced from the UK Prospective Diabetes Study Outcomes Model (UKPDS 82) and the SUSTAIN 7 clinical trial, while health utility values were obtained from published literature using the Chinese EQ-5D-5L value set. Long-term cost-effectiveness was projected through cohort simulation, with both one-way sensitivity analysis and probabilistic sensitivity analysis (PSA) conducted to evaluate the robustness of the model.ResultsAfter 25 years of simulation, the total cost for dulaglutide was ¥193,353.07, with 11.628 quality-adjusted life-years (QALYs) gained. The total cost for semaglutide was ¥240,925.08, yielding 11.900 QALYs. Compared with dulaglutide, semaglutide had an incremental cost-effectiveness ratio (ICER) of ¥174,904 per QALY gained, approximately twice China's 2023 per capita GDP (¥89,358). According to the Chinese Guidelines for Pharmacoeconomic Evaluation (2020), this result falls within the economically acceptable range (1 × GDP < ICER ≤ 3 × GDP). One-way sensitivity analysis showed that although health state utility values were the most influential parameter, the model results remained robust. PSA indicated that at a willingness-to-pay (WTP) threshold of 3 times the per capita GDP (¥268,074), semaglutide had an 89.6% probability of being considered economically acceptable.ConclusionFrom the perspective of China's basic medical insurance, semaglutide demonstrates cost-acceptable outcomes compared to dulaglutide in managing type 2 diabetes. This analysis provides crucial evidence for clinical decision-making and health policy formulation.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In a Chinese T2DM simulation, dulaglutide cost ¥193,353.07 over 25 years.

    In plain wordsA computer model projected dulaglutide costs of ¥193,353.07 over 25 years.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableProjected cost
    Study

    n: not reported in source

    Markov model simulating type 2 diabetes progression in China over 25 years
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    After 25 years of simulation, the total cost for dulaglutide was ¥193,353.07, with 11.628 quality-adjusted life-years (QALYs) gained.
    1 context sentence
    Summary · context
    This study employed a Markov model to simulate the disease progression of T2DM over a 25-year time horizon.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In a Chinese T2DM simulation, dulaglutide yielded 11.628 QALYs over 25 years.

    In plain wordsA computer model projected 11.628 quality-adjusted life-years with dulaglutide over 25 years.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableProjected QALYs
    Study

    n: not reported in source

    Markov model simulating type 2 diabetes progression in China over 25 years
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    After 25 years of simulation, the total cost for dulaglutide was ¥193,353.07, with 11.628 quality-adjusted life-years (QALYs) gained.
    1 context sentence
    Summary · context
    This study employed a Markov model to simulate the disease progression of T2DM over a 25-year time horizon.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03Computer modelNot a test of Semaglutide aloneIn silicoOther

    In a Chinese T2DM simulation, semaglutide cost ¥240,925.08 over 25 years.

    In plain wordsA computer model projected semaglutide costs of ¥240,925.08 over 25 years.

    Peptide
    Semaglutide
    Outcome
    Not applicableProjected cost
    Study

    n: not reported in source

    Markov model simulating type 2 diabetes progression in China over 25 years
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    The total cost for semaglutide was ¥240,925.08, yielding 11.900 QALYs.
    1 context sentence
    Summary · context
    This study employed a Markov model to simulate the disease progression of T2DM over a 25-year time horizon.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04Computer modelNot a test of Semaglutide aloneIn silicoOther

    In a Chinese T2DM simulation, semaglutide yielded 11.900 QALYs.

    In plain wordsA computer model projected 11.900 quality-adjusted life-years with semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableProjected QALYs
    Study

    n: not reported in source

    Markov model simulating type 2 diabetes progression in China over 25 years
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    The total cost for semaglutide was ¥240,925.08, yielding 11.900 QALYs.
    1 context sentence
    Summary · context
    This study employed a Markov model to simulate the disease progression of T2DM over a 25-year time horizon.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05Computer modelNot a test of Semaglutide aloneIn silicoOther

    In a Chinese T2DM model, semaglutide had an ICER of ¥174,904 per QALY versus dulaglutide.

    In plain wordsA computer model estimated semaglutide cost ¥174,904 per additional quality-adjusted life-year compared with dulaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableIncremental cost effectiveness
    Study

    n: not reported in source

    Markov model simulating type 2 diabetes progression in China over 25 years
    Comparator
    dulaglutide
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Compared with dulaglutide, semaglutide had an incremental cost-effectiveness ratio (ICER) of ¥174,904 per QALY gained, approximately twice China's 2023 per capita GDP (¥89,358).
    1 context sentence
    Summary · context
    This study employed a Markov model to simulate the disease progression of T2DM over a 25-year time horizon.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06Computer modelNot a test of Semaglutide aloneIn silicoOther

    In a Chinese T2DM model, semaglutide's ICER versus dulaglutide fell within the economically acceptable range.

    In plain wordsA computer model placed semaglutide versus dulaglutide within the Chinese economically acceptable range.

    Peptide
    Semaglutide
    Outcome
    Not applicableEconomic acceptability
    Study

    n: not reported in source

    Markov model simulating type 2 diabetes progression in China over 25 years
    Comparator
    dulaglutide
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    According to the Chinese Guidelines for Pharmacoeconomic Evaluation (2020), this result falls within the economically acceptable range (1 × GDP < ICER ≤ 3 × GDP).
    2 context sentences
    Summary · context
    Compared with dulaglutide, semaglutide had an incremental cost-effectiveness ratio (ICER) of ¥174,904 per QALY gained, approximately twice China's 2023 per capita GDP (¥89,358).
    Summary · context
    This study employed a Markov model to simulate the disease progression of T2DM over a 25-year time horizon.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07Computer modelNot a test of Semaglutide aloneIn silicoOther

    In the Chinese T2DM model comparing semaglutide and dulaglutide, utility values were most influential, but one-way sensitivity results remained robust.

    In plain wordsThe model comparison of semaglutide and dulaglutide remained robust in one-way sensitivity analysis.

    Peptide
    Semaglutide
    Outcome
    Not applicableModel sensitivity
    Study

    n: not reported in source

    Markov model simulating type 2 diabetes progression in China over 25 years
    Comparator
    dulaglutide
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    One-way sensitivity analysis showed that although health state utility values were the most influential parameter, the model results remained robust.
    1 context sentence
    Summary · context
    This study employed a Markov model to simulate the disease progression of T2DM over a 25-year time horizon.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In the Chinese T2DM model comparing dulaglutide and semaglutide, utility values were most influential, but one-way sensitivity results remained robust.

    In plain wordsThe model comparison of dulaglutide and semaglutide remained robust in one-way sensitivity analysis.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableModel sensitivity
    Study

    n: not reported in source

    Markov model simulating type 2 diabetes progression in China over 25 years
    Comparator
    semaglutide
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    One-way sensitivity analysis showed that although health state utility values were the most influential parameter, the model results remained robust.
    1 context sentence
    Summary · context
    This study employed a Markov model to simulate the disease progression of T2DM over a 25-year time horizon.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  9. 09Computer modelNot a test of Semaglutide aloneIn silicoOther

    In the Chinese T2DM model, semaglutide had an 89.6% economic acceptability probability at a ¥268,074 willingness-to-pay threshold.

    In plain wordsThe model gave semaglutide an 89.6% economic acceptability probability versus dulaglutide at the specified threshold.

    Peptide
    Semaglutide
    Outcome
    Not applicableProbability of economic acceptability
    Study

    n: not reported in source

    Markov model simulating type 2 diabetes progression in China over 25 years
    Comparator
    dulaglutide
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    PSA indicated that at a willingness-to-pay (WTP) threshold of 3 times the per capita GDP (¥268,074), semaglutide had an 89.6% probability of being considered economically acceptable.
    1 context sentence
    Summary · context
    This study employed a Markov model to simulate the disease progression of T2DM over a 25-year time horizon.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.